Aardvark Therapeutics Announces FDA Pediatric Disease Designation for PWS, Expansion of Phase 2 Clinical Trial

Aardvark Therapeutics recently announced the drug company has received Pediatric Disease Designation for PWS from the U.S. Food and Drug Administration (FDA), and will expand its Phase 2 clinical trial of oral ARD-101 in young adults with PWS. According to Aardvark Therapeutics, this FDA designation means the company is eligible for a Rare Pediatric Disease Priority Review Voucher when ARD-101 receives approval in PWS. ARD-101 is a first-in-class oral composition to reduce hyperphagia symptoms.

Click the button below to read Aardvark's full press release announcement.

If you are interested in learning more about Aardvark's ARD-101 clinical trial, click here to find study location details, criteria to participate, and more.

Share this!

Scroll to top